MYC and breast cancer: We previously reported that in human aggressive SGC cells [32] and in metastatic breast cancer cells [33], introduction of the progesterone receptor and treatment with progestin was sufficient to reduce Id1 expression, down-regulation of c-myc and MMP-9, up-regulation of p21 and consequently a decrease in the aggressive phenotype of the cells.